NeuroActiva
Clinical-stage biopharmaceutical company developing orally available small-molecule therapeutics and a controlled-release infusion system. Pipeline focuses on neurodegenerative disorders, metabolic diseases, stroke and rare diseases. Maintains AI-enabled drug-discovery and digital-phenotyping capabilities and a systems-level translational platform to prioritize multi‑indication development.
Industries
Nr. of Employees
small (1-50)
NeuroActiva
2570 N. First Street, 2nd Floor, San Jose, CA 95131 USA
Products
NA-831
Orally administered investigational small molecule reported to promote neuroprotection and adult neurogenesis for mild-to-moderate Alzheimer’s disease; Phase 2A completed and Phase 3 planned.
NA-931
Oral small-molecule quadruple receptor agonist targeting IGF-1, GLP-1, GIP and glucagon for obesity and metabolic disorders; Phase 1–2 results reported.
NA-921
Oral investigational therapy for Rett Syndrome; reported Phase 2/3 results and ongoing Phase 3 protocol.
NA-704
Investigational injectable small molecule intended to stimulate neurogenesis and reduce muscular spasticity for ALS and related disorders; compatible with controlled-release infusion systems.
NA-911
Investigational neuroprotective small molecule developed for treatment and prevention of ischemic stroke; reported therapeutic window and safety data.
NA-941
Oral small-molecule quadruple receptor agonist candidate for metabolic dysfunction-associated steatohepatitis (MASH/NAFLD) with Phase 1b and Phase 2 study programs.
NA-831
Orally administered investigational small molecule reported to promote neuroprotection and adult neurogenesis for mild-to-moderate Alzheimer’s disease; Phase 2A completed and Phase 3 planned.
NA-931
Oral small-molecule quadruple receptor agonist targeting IGF-1, GLP-1, GIP and glucagon for obesity and metabolic disorders; Phase 1–2 results reported.
NA-921
Oral investigational therapy for Rett Syndrome; reported Phase 2/3 results and ongoing Phase 3 protocol.
NA-704
Investigational injectable small molecule intended to stimulate neurogenesis and reduce muscular spasticity for ALS and related disorders; compatible with controlled-release infusion systems.
NA-911
Investigational neuroprotective small molecule developed for treatment and prevention of ischemic stroke; reported therapeutic window and safety data.
NA-941
Oral small-molecule quadruple receptor agonist candidate for metabolic dysfunction-associated steatohepatitis (MASH/NAFLD) with Phase 1b and Phase 2 study programs.
Services
Machine-learning and high-performance computing services to analyze transcriptional and high-content datasets for lead identification and biomarker development.
Machine-learning and high-performance computing services to analyze transcriptional and high-content datasets for lead identification and biomarker development.
Expertise Areas
- Clinical trial management
- Neurodegenerative disease therapeutics
- Metabolic disease therapeutics
- AI-driven drug discovery and biomarker development
Key Technologies
- Oral small-molecule therapeutics
- Multi-receptor metabolic agonist approaches
- Blood–brain barrier penetrant compounds
- Modulation of neurogenesis-related pathways
News & Updates
Company presented Phase 2 clinical trial results of an oral quadruple receptor agonist for obesity at EASD 2025.
Company presented Phase 2 clinical protocol for NA-941 and trials of NA-931/NA-941 for obesity and MASH at Paris MASH 2025.
Company announced Phase 2/3 results for an oral therapy for Rett Syndrome reporting efficacy and safety.
Nanoporous membrane controlled-release infusion system reported as approved for marketing in the United States.
Reported Phase 1 and Phase 2 clinical data for an oral quadruple receptor agonist showing dose-dependent weight loss and favorable safety/tolerability.
Company presented Phase 2 clinical trial results of an oral quadruple receptor agonist for obesity at EASD 2025.
Company presented Phase 2 clinical protocol for NA-941 and trials of NA-931/NA-941 for obesity and MASH at Paris MASH 2025.
Company announced Phase 2/3 results for an oral therapy for Rett Syndrome reporting efficacy and safety.
Nanoporous membrane controlled-release infusion system reported as approved for marketing in the United States.
Reported Phase 1 and Phase 2 clinical data for an oral quadruple receptor agonist showing dose-dependent weight loss and favorable safety/tolerability.